Clinical Trial Details
| Trial ID: | L6034 |
| Source ID: | NCT00361738 |
| Associated Drug: | Ave2268 |
| Title: | Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: AVE2268 |
| Outcome Measures: | Primary: Change in Mean Plasma Glucose (MPG) from baseline to week 4. | Secondary: Glucose parameters (change from baseline to week 4 in fasting and post prandial plasma glucose) ; Change in HbA1c and fructosamine ; Safety: physical examination, adverse events, ECG, laboratory tests |
| Sponsor/Collaborators: | Sponsor: Sanofi |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 317 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2006-07 |
| Completion Date: | 2008-01 |
| Results First Posted: | |
| Last Update Posted: | 2009-02-09 |
| Locations: | Sanofi-Aventis Administrative Office, San Isidro, Argentina|Sanofi-Aventis Administrative Office, Cove, New South Wales, Australia|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Midrand, South Africa |
| URL: | https://clinicaltrials.gov/show/NCT00361738 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|